Clinical trialPhase 1Active not recruiting
Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies
An Open-Label, Multicenter, Phase 1/1b Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies
- Outcome
- Ongoing
- Phase
- Phase 1
- Status
- Active not recruiting
- Study type
- Interventional
- Start
- 19 April 2023
- Listed end
- 31 October 2026
- Enrollment
- 130 participants
- Sites
- 18
- Primary outcomes
- Incidence of Dose Limiting Toxicities (DLT); Incidence of Adverse Events (AE) and Serious Adverse Events (SAE); Incidence of Clinically Significant Laboratory Abnormalities
- Sponsor type
- Industry
- Results posted
- No
- Last update
- 1 June 2026
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This study is a first-in-human (FIH), Phase 1/1b, open-label, multicenter dose escalation and dose expansion study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of JANX008 in adult subjects with advanced or metastatic carcinoma expressing EGFR.